Immunic, Inc.

IMUX · NASDAQ
Analyze with AI
9/30/2025
6/30/2025
3/31/2025
12/31/2024
Operating Activities
Net Income-$25,579-$26,820-$25,473-$25,175
Dep. & Amort.$40$43$43$35
Deferred Tax$0$0$0$0
Stock-Based Comp.$0$1,899$2,042$0
Change in WC$1,737$214$1,559$71
Other Non-Cash$3,662$55$53$2,106
Operating Cash Flow-$20,140-$24,609-$21,776-$22,963
Investing Activities
PP&E Inv.-$67-$36-$47-$3
Net Acquisitions$0$0$0$0
Inv. Purchases$0$0$0$0
Inv. Sales/Matur.$0$0$0$0
Other Inv. Act.$0$0$0$0
Investing Cash Flow-$67-$36-$47-$3
Financing Activities
Debt Repay.$0$0$0$0
Stock Issued$65,395$0$0$77
Stock Repurch.$0$123$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.-$65,395$65,395$0$0
Financing Cash Flow$0$65,518$0$77
Forex Effect$29$133$459-$514
Net Chg. in Cash-$20,178$41,006-$21,364-$23,403
Supplemental Information
Beg. Cash$55,310$14,304$35,668$59,071
End Cash$35,132$55,310$14,304$35,668
Free Cash Flow-$20,207-$24,645-$21,823-$22,966
Immunic, Inc. (IMUX) Financial Statements & Key Stats | AlphaPilot